The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XX.g

Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

In patients exposed to TNF-alpha antagonists, tuberculosis can be pulmonary or extrapulmonary. The expression of pulmonary TB in such patients may differ from that in person unexposed to such drugs (PMID: 24365560). A search for LTBI prior to comencement of treatment is indicated using IGRA test (PMID 20810871)

Publications

Wang X, Wong SH, Wang XS, Tang W, Liu CQ, Niamul G, Wu B, Tam LS, Wu JCY, Chan FKL, Sung JJY, Ng SC

Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region.

Rheumatology (Oxford, England) 2018 Dec 14;; — 2018 Dec 14

Kang J, Jeong DH, Han M, Yang SK, Byeon JS, Ye BD, Park SH, Hwang SW, Shim TS, Jo KW

Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease.

Journal of Korean medical science 2018 Nov 19;33;e292 — 2018 Nov 19 — e292

Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB

Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Rheumatology (Oxford, England) 2018 06 01;57;997-1001 — 2018 06 01 — 997-1001

Chan MJ, Wen YH, Huang YB, Chuang HY, Tain YL, Lily Wang YC, Hsu CN

Risk of tuberculosis comparison in new users of antitumour necrosis factor-? and with existing disease-modifying antirheumatic drug therapy.

Journal of clinical pharmacy and therapeutics 2018 Apr;43;256-264 — 2018 Apr — 256-264

Lee JW, Choi CH, Park JH, Kim JW, Kang SB, Koo JS, Kim YH, Kim YS, Joo YE, Chang SK

Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease.

Intestinal research 2016 Apr;14;146-51 — 2016 Apr — 146-51

Chang CH, Ruan SY, Huang CT

Disseminated tuberculosis in a patient treated with biologics.

American journal of respiratory and critical care medicine 2015 Mar 01;191;592-3 — 2015 Mar 01 — 592-3

Ishiguro T, Takayanagi N, Kagiyama N, Yanagisawa T, Sugita Y

Characteristics of tuberculosis in patients with rheumatoid arthritis: a retrospective single-center study.

Internal medicine (Tokyo, Japan) 2014;53;1291-8 — 2014 — 1291-8

Huang LK, Wu MH, Chang SC

Radiological manifestations of pulmonary tuberculosis in patients subjected to anti-TNF-? treatment.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2014 Jan;18;95-101 — 2014 Jan — 95-101

Cappell MS, Saad A, Bortman JS, Amin M

Ileocolonic tuberculosis clinically, endoscopically, and radiologically mimicking Crohn's disease: disseminated infection after treatment with infliximab.

Journal of Crohn's & colitis 2014 Jun;8;560-2 — 2014 Jun — 560-2

Ribeiro C, Correia AM, Duarte R

Tuberculosis and TNF? antagonists--what are we missing?

Revista portuguesa de pneumologia 2014 Jan-Feb;20;53-4 — 2014 Jan-Feb — 53-4

Navarra SV, Tang B, Lu L, Lin HY, Mok CC, Asavatanabodee P, Suwannalai P, Hussein H, Rahman MU

Risk of tuberculosis with anti-tumor necrosis factor-? therapy: substantially higher number of patients at risk in Asia.

International journal of rheumatic diseases 2014 Mar;17;291-8 — 2014 Mar — 291-8

Lee SK, Kim SY, Kim EY, Jung JY, Park MS, Kim YS, Kim SK, Chang J, Kang YA

Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea.

Lung 2013 Oct;191;565-71 — 2013 Oct — 565-71

Jauregui-Amezaga A, Turon F, Ordás I, Gallego M, Feu F, Ricart E, Panés J

Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.

Journal of Crohn's & colitis 2013 Apr;7;208-12 — 2013 Apr — 208-12

Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, McFarland B, Austin D, Radcliffe L, Suhler E, Choi D, Rosenbaum JT, Herrinton LJ

Mycobacterial diseases and antitumour necrosis factor therapy in USA.

Annals of the rheumatic diseases 2013 Jan;72;37-42 — 2013 Jan — 37-42

Ferrara G, Murray M, Winthrop K, Centis R, Sotgiu G, Migliori GB, Maeurer M, Zumla A

Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNF? drugs.

Current opinion in pulmonary medicine 2012 May;18;233-40 — 2012 May — 233-40

Keyser FD

Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.

Current rheumatology reviews 2011 Feb;7;77-87 — 2011 Feb — 77-87

Mariette X, Gottenberg JE, Ravaud P, Combe B

Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.

Rheumatology (Oxford, England) 2011 Jan;50;222-9 — 2011 Jan — 222-9

Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, , Symmons DP,

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Annals of the rheumatic diseases 2010 Mar;69;522-8 — 2010 Mar — 522-8

Lalvani A, Millington KA

Screening for tuberculosis infection prior to initiation of anti-TNF therapy.

Autoimmunity reviews 2008 Dec;8;147-52 — 2008 Dec — 147-52

Patkar NM, Teng GG, Curtis JR, Saag KG

Association of infections and tuberculosis with antitumor necrosis factor alpha therapy.

Current opinion in rheumatology 2008 May;20;320-6 — 2008 May — 320-6

Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO

Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004 May 01;38;1261-5 — 2004 May 01 — 1261-5

Long R, Gardam M

Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2003 Apr 29;168;1153-6 — 2003 Apr 29 — 1153-6